Adrien Lemoine MSc

Adrien brings nearly 20 years of experience creating value for pharma and biotech companies. His responsibilities at Orchard Therapeutics include overseeing business development, program management, program leadership, and portfolio strategy for the company. Since joining Orchard in October 2016, he has led the build-out of Orchard’s industry-leading gene therapy pipeline through multiple in-licensing deals, notably the acquisition of GSK’s gene therapy portfolio in April 2018.

Prior to joining Orchard, Adrien was executive director, corporate strategy and development at AstraZeneca where he led M&A activities as well as successful out-licensing, divestments, and new company spinoff projects. He also served as a member of Corvidia Therapeutics’ board of directors. Prior to AstraZeneca, Adrien spent nine years at GSK; his most recent role was strategy & operations director in the rare disease unit, working in particular on GSK’s ex vivo autologous HSC gene therapy portfolio. He was a member of the advisory committee for Kurma BioFund II, a venture capital fund with a special focus on rare diseases. His experience at GSK also encompasses European and global roles of increasing seniority in R&D portfolio strategy and commercial analysis. He started his career as a strategy consultant at Alcimed in Paris, France, supporting the development of biotechnology startup companies.